An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

著者: Christopher G. Wood, Pramod K. Srivastava, Ronald M. Bukowski, Louis Lacombe, Gorelov Ai, S. Gorelov, Peter Mulders, Henryk Zieliński, Axel Hoos, Florentina Teofilovici, Leah Isakov, Robert C. Flanigan, Robert A. Figlin, Renu Gupta, Bernard Escudier - The Lancet 2008 被引用: 330